Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | MIF | P14174 | 1/20 | 0.30 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.30 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.30 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.30 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.30 |
| ▸ | HTR3B | O95264 | 1/20 | 0.30 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.30 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3183185 | 0.82 | TAAR1 (0.46) | ALDH1A1TAAR1HTR3ESLC22A2SLC22A1 | |
| SCHEMBL6001526 | 0.77 | LMNA (0.39) | ALDH1A1 | |
| SCHEMBL49730 | 0.74 | LTA4H (0.47) | ALDH1A1 | |
| SCHEMBL6774703 | 0.72 | MMP2 (0.37) | KCNA3 | |
| SCHEMBL3937554 | 0.71 | ALDH1A1 (0.39) | ALDH1A1MIFHTR3ESLC22A2SLC22A1 | |
| SCHEMBL1853476 | 0.71 | ALDH1A1 (0.39) | ALDH1A1MIFHTR3ESLC22A2SLC22A1 | |
| SCHEMBL49789 | 0.71 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL377077 | 0.71 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL4631197 | 0.70 | TSHR (0.50) | ALDH1A1 | |
| SCHEMBL1009986 | 0.64 | KCNA3 (0.67) | ALDH1A1TAAR1RECQLKCNA3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087758-B2 | Quinoline inhibitors of hyaki and hyak3 kinases | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| US-20050043352-A1 | Quinoline inhibitors of hyaki and hyak3 kinases | SMITHKLINE BEECHAM CORPORATION | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043352-A1 | Quinoline inhibitors of hyaki and hyak3 kinases | HIPK3, HIPK1, HYPK | ALDH1A1 3983/4885TAAR1 3994/4885RECQL 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.